Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Feb;32(2):209–212. doi: 10.1128/aac.32.2.209

Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans.

C E Hughes 1, R L Bennett 1, I C Tuna 1, W H Beggs 1
PMCID: PMC172136  PMID: 2834995

Abstract

We have compared the activities of fluconazole and ketoconazole against ketoconazole-susceptible and -resistant strains of Candida albicans in a neutropenic-site rabbit model. Oral treatment with fluconazole resulted in much higher serum and extravascular concentrations of this antifungal agent than did comparable doses of ketoconazole. Fluconazole had no additional in vivo activity against the ketoconazole-susceptible strains; no fungicidal activity was observed with peak drug levels as high as approximately 75 micrograms/ml in the infection sites. Significant fungistatic activity against the ketoconazole-resistant strains was observed with fluconazole treatment (80 mg/kg), but not with less fluconazole (20 mg/kg) or with ketoconazole (approximately 67 mg/kg). In vitro susceptibility tests separated the ketoconazole-susceptible strains from the ketoconazole-resistant strains, but the results were variable when the resistant strains were tested with fluconazole.

Full text

PDF
209

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beggs W. H. Growth phase in relation to ketoconazole and miconazole susceptibilities of Candida albicans. Antimicrob Agents Chemother. 1984 Mar;25(3):316–318. doi: 10.1128/aac.25.3.316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bodet C. A., 3rd, Jorgensen J. H., Drutz D. J. Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol. 1985 Aug;22(2):157–160. doi: 10.1128/jcm.22.2.157-160.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Galgiani J. N., Stevens D. A. Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother. 1976 Oct;10(4):721–728. doi: 10.1128/aac.10.4.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Horseburgh C. R., Jr, Kirkpatrick C. H., Teutsch C. B. Ketoconazole and the liver. Lancet. 1982 Apr 10;1(8276):860–860. doi: 10.1016/s0140-6736(82)91915-8. [DOI] [PubMed] [Google Scholar]
  5. Hughes C. E., Beggs W. H. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother. 1987 Feb;19(2):171–174. doi: 10.1093/jac/19.2.171. [DOI] [PubMed] [Google Scholar]
  6. Hughes C. E., Bennett R. L., Beggs W. H. Broth dilution testing of Candida albicans susceptibility to ketoconazole. Antimicrob Agents Chemother. 1987 Apr;31(4):643–646. doi: 10.1128/aac.31.4.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hughes C. E., Peterson L. R., Beggs W. H., Gerding D. N. Ketoconazole and flucytosine alone and in combination against Candida spp. in a neutropenic site in rabbits. J Antimicrob Chemother. 1986 Jul;18(1):65–72. doi: 10.1093/jac/18.1.65. [DOI] [PubMed] [Google Scholar]
  8. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Perfect J. R., Durack D. T. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother. 1985 Jul;16(1):81–86. doi: 10.1093/jac/16.1.81. [DOI] [PubMed] [Google Scholar]
  10. Perfect J. R., Savani D. V., Durack D. T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother. 1986 Apr;29(4):579–583. doi: 10.1128/aac.29.4.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Peterson L. R., Gerding D. N. Prediction of cefazolin penetration in high- and low-protein-containing extravascular fluid: new method for performing simultaneous studies. Antimicrob Agents Chemother. 1978 Oct;14(4):533–538. doi: 10.1128/aac.14.4.533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rogers T. E., Galgiani J. N. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 1986 Sep;30(3):418–422. doi: 10.1128/aac.30.3.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ryley J. F., Wilson R. G., Barrett-Bee K. J. Azole resistance in Candida albicans. Sabouraudia. 1984;22(1):53–63. [PubMed] [Google Scholar]
  14. Savani D. V., Perfect J. R., Cobo L. M., Durack D. T. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987 Jan;31(1):6–10. doi: 10.1128/aac.31.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Troke P. F., Andrews R. J., Brammer K. W., Marriott M. S., Richardson K. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother. 1985 Dec;28(6):815–818. doi: 10.1128/aac.28.6.815. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES